1. The Preclinical and Ind Application Stages
Before any human testing occurs, manufacturers must conduct extensive preclinical research using laboratory and animal models. This foundational work typically spans three to six years and generates the safety data required to support an Investigational New Drug (IND) application. The IND is the legal gateway to human trials and must demonstrate that the drug is safe enough to test in people. From a practitioner's perspective, the IND application is where many regulatory disputes begin, because the FDA's assessment of preclinical data often determines whether trials can proceed on the company's timeline.
Ind Application Requirements and Fda Review
An IND application must include detailed chemistry, manufacturing, and controls information; pharmacology and toxicology data; and a protocol for the proposed clinical trial. The FDA has 30 days to review the IND and either approve it, issue a "clinical hold," or request additional information. A clinical hold stops the trial until deficiencies are resolved. Companies that fail to disclose known safety signals or misrepresent preclinical data face not only regulatory delay but also potential criminal liability under the Federal Food, Drug, and Cosmetic Act. The stakes here are substantial, and early legal counsel can prevent costly missteps.
New York Regulatory Coordination
In New York, institutional review boards (IRBs) at research hospitals and universities must also approve any IND-sponsored trial conducted within the state. New York's Department of Health maintains separate oversight authority for certain trials, particularly those involving vulnerable populations. This dual federal-state review structure means that a company can receive FDA approval for an IND but still face state-level delays or conditions. Understanding New York's specific IRB and Department of Health requirements from the outset prevents scheduling conflicts and regulatory surprises.
2. Clinical Trial Phases and Regulatory Compliance
Clinical development proceeds through three main phases, each designed to answer different safety and efficacy questions. Phase 1 involves 20–100 healthy volunteers and focuses on safety and dosage. Phase 2 enrolls 100–500 patient volunteers and examines whether the drug works for its intended condition. Phase 3 expands to 1,000–5,000 patients and confirms efficacy, monitors side effects, and compares the drug to existing treatments. Regulatory compliance during trials is not optional; violations can result in trial termination, data invalidation, and regulatory sanctions.
Adverse Event Reporting and Compliance Obligations
Sponsors must report serious adverse events to the FDA within 15 days. Failure to report known safety signals exposes companies to criminal prosecution for obstruction of justice and FDA enforcement actions. In practice, these cases are rarely as clean as the statute suggests; disputes often turn on whether a company knew or should have known about a safety issue. A pharmaceutical manufacturer in New Jersey, for example, failed to report a pattern of liver toxicity observed in Phase 2 trials, and was later prosecuted for knowingly concealing material safety data from the FDA. The company faced both civil penalties exceeding $100 million and criminal charges against executives. This underscores why robust adverse event monitoring systems and legal review of safety reports must be built into trial operations from day one.
3. New Drug Application and Marketing Approval
Once clinical data demonstrates safety and efficacy, the sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA). The FDA reviews the application under one of two timelines: standard review (10 months) or priority review (6 months for drugs addressing unmet medical needs). The NDA must include all clinical and nonclinical data, proposed labeling, and manufacturing information. Approval is not guaranteed; the FDA may issue a "Complete Response Letter" requesting additional data or studies before it will approve the drug.
Labeling, Indication Scope, and Post-Approval Risk
FDA approval grants the right to market a drug only for the specific indications (uses) and patient populations described in the approved labeling. Off-label marketing, promotional claims that exceed approved indications, or failure to include required warnings constitute violations of the Federal Food, Drug, and Cosmetic Act and can trigger both FDA enforcement and criminal liability. Pharmaceutical companies have faced multi-billion-dollar settlements for promoting drugs for unapproved uses. The connection between FDA approval scope and criminal drug possession law may seem distant, but marketing a drug in ways that mislead physicians about safety or efficacy can result in criminal charges against company officers and the company itself.
4. Post-Approval Surveillance and Evolving Legal Risk
FDA approval does not end regulatory obligations. Manufacturers must conduct post-marketing surveillance (Phase 4) to monitor long-term safety and report adverse events continuously. The FDA can withdraw approval or impose restrictions if new safety data emerges. Companies operating in the pharmaceutical space must also navigate FDA regulatory frameworks that extend beyond drug approval to manufacturing, distribution, and advertising. Compliance failures in any of these areas create legal exposure.
Recalls, Withdrawals, and Enforcement Actions
When safety issues emerge post-approval, the FDA may request a voluntary recall or issue a mandatory withdrawal order. The table below outlines common enforcement actions and their triggers:
| Warning Letter | Significant regulatory violation; 15 days to respond |
| Untitled Letter | Less serious violation; advisory in nature |
| Seizure | Product removed from commerce; criminal referral possible |
| Injunction | Court order halting manufacturing or distribution |
| Criminal Prosecution | Knowing violation; executives and company liable |
Companies that receive a Warning Letter must investigate the violation, implement corrective actions, and document compliance. Failure to respond adequately invites escalation to seizure or criminal referral.
5. Strategic Considerations for Pharmaceutical Stakeholders
The FDA drug approval process is not a one-time event; it is the beginning of a continuous compliance obligation. Companies should build legal review into every stage, from preclinical data generation through post-market surveillance. Early counsel involvement in IND preparation, adverse event assessment, and labeling review prevents costly delays and regulatory sanctions. Investors and board members should understand that FDA compliance failures expose not only the company to civil penalties but also officers and employees to criminal liability. For any organization operating in pharmaceutical development or distribution, the question is not whether to consult legal counsel, but when to do so and how deeply to integrate compliance into operational decision-making.
04 Feb, 2026
